Breast Neoplasms trials recruiting in New York
All Breast Neoplasms trials nationally
13
Recruiting in New York
20
Cities with sites
Cities in New York
New York 11Rochester 4Stony Brook 3Albany 2Brooklyn 2The Bronx 2Westbury 2Babylon 1Bay Shore 1Buffalo 1Commack 1Harrison 1
Recruiting trials in New York
- A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
- A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
- A Study of Breast Cancer Risk Factors and Outcomes of People in Florida
- A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
- A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
- A Study of LY4257496 in Participants With Cancer (OMNIRAY)
- A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer
- A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
- A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
- ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
- Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer